Welcome to our dedicated page for Outset Medical SEC filings (Ticker: OM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Trying to locate how many Tablo consoles Outset Medical shipped last quarter or what the FDA required in its latest warning letter can mean wading through hundreds of pages. Outset Medical SEC filings are especially dense because they blend medical-device regulations, reimbursement economics and consumable margin data. That complexity is the problem we solve. Our AI-powered summaries translate each section of every document into plain English so you can move straight to the numbers that matter.
Whether you need the Outset Medical quarterly earnings report 10-Q filing or want an Outset Medical annual report 10-K simplified, the platform delivers real-time documents from EDGAR and instant, sentence-by-sentence explanations. Form types are tied to practical questions: 8-Ks flag new FDA clearances—see “Outset Medical 8-K material events explained.” Proxy statements break down incentive plans—explore “Outset Medical proxy statement executive compensation.” And if you are tracking leadership conviction, our dashboard highlights “Outset Medical insider trading Form 4 transactions,” including “Outset Medical executive stock transactions Form 4,” with alerts the moment they post.
Advanced tools layer expert context on top of filings. Interactive charts compare segment margins over time, and AI callouts spotlight supply-chain risk buried deep in footnotes—perfect for “understanding Outset Medical SEC documents with AI.” Need a quick share with colleagues? One-click exports package the full “Outset Medical earnings report filing analysis.” Because updates stream continuously, you never miss an “Outset Medical Form 4 insider transactions real-time.” Complex dialysis disclosures, simplified: that’s the Stock Titan advantage.
Marc Nash, Outset Medical's EVP, Research & Development, Operations and Services, received a grant of 5,617 restricted stock units (RSUs) on 08/25/2025. Each RSU converts to one share of common stock at no purchase price ($0.0). Following the grant, the reporting person beneficially owned 48,515 shares. The RSUs vest 33.33% on August 15, 2026, with the remaining 66.67% vesting in equal quarterly installments over the subsequent two years on each February 15, May 15, August 15 and November 15, contingent on continuous service through each vesting date.
Insider Form 4 summary: Leslie Trigg, Chair and CEO of Outset Medical, sold 904 shares of common stock on 08/15/2025 at $12.88 per share to satisfy tax withholding related to the vesting of 1,769 restricted stock units granted on January 6, 2023 and January 12, 2024. The sale is described as a "sell to cover" to meet withholding obligations and not a discretionary trade. After the transaction, Trigg beneficially owns 122,328 shares directly and 42,250 indirectly (41,666 via the Trigg 2002 Rev Trust and 584 via the Trigg Family Trust).
Marc Nash, SVP Operations and R&D and director of Outset Medical (OM), reported a non-discretionary sell-to-cover transaction on 08/15/2025. He sold 243 shares of Outset common stock at $12.88 per share to satisfy tax withholding related to the vesting of an aggregate 673 restricted stock units granted on March 15, 2023, July 24, 2023, and January 12, 2024. After the transaction, the reporting person beneficially owned 42,898 shares directly. The Form 4 was signed by John L. Brottem on behalf of Marc Nash on 08/18/2025.
This filing is a routine insider tax-withholding sale and the filer states it was not a discretionary trade.
John L. Brottem, General Counsel and director of Outset Medical, reported a routine sell-to-cover transaction on 08/15/2025. He sold 383 shares of Outset Medical common stock at $12.88 per share to satisfy tax withholding obligations arising from the vesting of 748 RSU shares awarded on January 6, 2023 and January 12, 2024. After the transaction, Brottem beneficially owned 46,883 shares directly. The filing specifies the sale was to cover taxes and was not a discretionary trade by the reporting person.
Outset Medical, Inc. insider filing reports a proposed Rule 144 sale of 904 shares of common stock via Morgan Stanley Smith Barney, with an aggregate market value of $11,643.52 and an approximate sale date of 08/15/2025. The shares were acquired the same day, 08/15/2025, as the settlement of vested restricted stock units issued as equity compensation for services rendered. The filer also disclosed a prior sale on 05/15/2025 of 935 shares for gross proceeds of $16,646.12. Outstanding common shares are listed as 17,766,193, indicating the transactions are a small fraction of total shares outstanding. The filing includes the standard attestation that the seller is not aware of undisclosed material adverse information.
Outset Medical, Inc. (OM) reported a proposed sale under Rule 144 of 383 shares of Common Stock through Morgan Stanley Smith Barney, with an aggregate market value of $4,933.04, targeted for sale on 08/15/2025 on NASDAQ. The filing shows the securities were acquired as settlement of vested restricted stock units on 08/15/2025 (748 shares) as equity compensation. The filer also reports a prior sale of 396 shares on 05/15/2025 that generated $7,057.86. The notice includes the customary representation that the seller is not aware of undisclosed material adverse information.
Form 144 filing for Outset Medical, Inc. (OM) documents a proposed sale of 243 shares of Common Stock through Morgan Stanley Smith Barney with an aggregate market value of $3,129.84, to be sold on 08/15/2025 on NASDAQ. The shares were acquired on 08/15/2025 as settlement of vested restricted stock units and were paid as equity compensation for services. The filer also disclosed a prior sale of 252 shares on 05/15/2025 generating gross proceeds of $4,490.50. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.
FAQ
What is the current stock price of Outset Medical (OM)?
What is the market cap of Outset Medical (OM)?
